Article - 07/03/2016 Looking at the control of cellular homeostasis Many biological processes that occur in our body are driven and controlled by protein complexes. In order to better understand these processes, biochemist Prof. Dr. Florian Stengel from the University of Konstanz is developing methods that will eventually make it possible to study the architecture, interactions and general dynamics of intact protein complexes quantitatively and in detail. Stengel combines structural mass spectrometry methods with…https://www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-control-of-cellular-homeostasis
Article - 03/03/2016 Liquid biopsies – beacons of hope for cancer diagnosis? Researchers around the world, including researchers from the Freiburg University Medical Center, are working on developing simple blood tests, so-called liquid biopsies, that can be used to obtain accurate information about tumour staging and the progress of therapy. An international liquid biopsy symposium was held in Freiburg in October 2015 and has produced valuable insights.https://www.gesundheitsindustrie-bw.de/en/article/news/liquid-biopsies-beacons-of-hope-for-cancer-diagnosis
Article - 02/02/2016 EU consortium to speed up innovations in the healthcare sector EIT Health is a large-scale European project launched in December 2014 that aims to help people in Europe to live a healthier life and stay active as they grow older. The consortium brings together 140 leading companies and institutions from 14 European countries and has a total budget of two billion euros. It is one of the largest networks worldwide in the healthcare sector.https://www.gesundheitsindustrie-bw.de/en/article/news/eu-consortium-to-speed-up-innovations-in-the-healthcare-sector
Article - 21/01/2016 Genome research as information research DNA sequencing has become indispensable in modern science. Innovative advances that will bring about changes in the life sciences and medicine are due to rapid developments in genome analysis technologies. In the interview below, Peter Pohl, CEO and co-founder of GATC Biotech AG, explains why DNA sequencing will become even more important in future. https://www.gesundheitsindustrie-bw.de/en/article/news/genome-research-as-information-research
Article - 17/11/2015 Novel hydrogels as functional materials In the ”NanoBioMater”project house, researchers from the University of Stuttgart are working to develop novel hydrogels with integrated biocompatible scaffold structures. Their aim is to make the materials suitable for producing innovative components for environmental and food analytics as well as medical applications. The hydrogels could potentially be used in diagnostic biosensors and the controlled release of medical compounds. https://www.gesundheitsindustrie-bw.de/en/article/news/novel-hydrogels-as-functional-materials
Telemedicine - 19/10/2015 Medical apps – potential helpers for physicians and patients Can smartphones become health counsellors for patients or diagnostic tools for doctors? The answer is yes, at least technically. However, health apps that comply with valid medical device regulations are still rather rare in Germany. Many health insurance companies are reluctant to pay for the use of these modern tools because the legal framework is inadequate and doctors are not yet fully capable of using them. Nevertheless, the use of such…https://www.gesundheitsindustrie-bw.de/en/article/news/medical-apps-potential-helpers-for-physicians-and-patients
Article - 24/09/2015 New test system for detection of HPV-related oral cavity cancers The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of…https://www.gesundheitsindustrie-bw.de/en/article/news/new-test-system-for-detection-of-hpv-related-oral-cavity-cancers
Article - 21/09/2015 Hans-Peter Deigner: "Optimisation of lateral flow assays using nanoparticles." Nanoparticles are already used in many materials and areas, ranging from textiles to scientific and medical research. The global scientific community is keenly interested in nanoparticle research and Prof. Dr. Hans-Peter Deigner, professor in the Faculty of Medical and Life Sciences at Furtwangen University of Applied Sciences (HFU) is no exception. Deigner works on optimising nanoparticles for application in lateral flow assays. As well as…https://www.gesundheitsindustrie-bw.de/en/article/news/hans-peter-deigner-optimisation-of-lateral-flow-assays-using-nanoparticles
Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 Biametrics GmbH concludes financing round with 3.1 Million Euro Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
Article - 15/06/2015 Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic…https://www.gesundheitsindustrie-bw.de/en/article/news/centre-for-personalised-medicine-in-tuebingen-developing-tailor-made-treatments-for-patients
Overview Diagnostics The latest articles, press releases and dossiers on diagnostics in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/diagnostics
The Baden-Württemberg healthcare industry Medical technology Medical technology is indispensible for human health and contributes a great deal to improving the quality of our lives. The field of medical technology covers many areas. These range from simple disposable products and consumables such as dressing materials and other clinical supplies, to IT-related telemedicine, homecare and eHealth systems as well as high-technology and innovative robotics, imaging, diagnostics and life-support systems. 842…https://www.gesundheitsindustrie-bw.de/en/location/medtech
The Baden-Württemberg healthcare industry The pharmaceutical industry Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.https://www.gesundheitsindustrie-bw.de/en/location/pharma
The Baden-Württemberg healthcare industry The biotechnology sector Baden-Württemberg is currently home to 188 biotechnology companies. In addition to dedicated biotechnology companies, this also includes bioinformatics, diagnostics and analytics companies that use modern biotechnology methods or focus on biotechnological production.https://www.gesundheitsindustrie-bw.de/en/location/biotech
Article - 23/03/2015 cytena GmbH facilitates the separation of single cells cytena GmbH, a start-up company which was spun out from the Department of Microscystems Engineering (IMTEK) at the University of Freiburg in 2014, has developed a device that enables single cells to be deposited safely and gently using a single-cell printer called cy-Clone. Once processed, the cells can be used to study tumour heterogeneity and to create clonal cell lines for producing antibodies. https://www.gesundheitsindustrie-bw.de/en/article/news/cytena-gmbh-facilitates-the-separation-of-single-cells
Article - 26/01/2015 A biomarker as indicator for the likelihood of developing aggressive prostate cancer Overexpression of the protein BAZ2A, which leads to alterations in epigenetic patterns, increases the malignant properties of tumour cells, including their mobility and their ability to form metastases. The findings of a team of researchers from Heidelberg, Zurich and Hamburg may have led to the discovery of an urgently needed prognostic biomarker that would make it possible to differentiate aggressive prostate cancer from the less malignant…https://www.gesundheitsindustrie-bw.de/en/article/news/a-biomarker-as-indicator-for-the-likelihood-of-developing-aggressive-prostate-cancer
Article - 26/01/2015 Pooling efforts against infectious diseases in Germany Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…https://www.gesundheitsindustrie-bw.de/en/article/news/pooling-efforts-against-infectious-diseases-in-germany
Article - 19/01/2015 Kay Gottschalk and the physics of cells You learn a great deal about the physical aspects of cells when you talk to Prof. Dr. Kay-E. Gottschalk. For example, their ability to react as solid and liquid, to adapt their environment to suit themselves and to exert and respond to forces. The 42-year-old has great respect for the smallest of living units, i.e. cells, which he calls smart composite materials. Working on the boundaries of medicine, biology, chemistry and physics, Gottschalk…https://www.gesundheitsindustrie-bw.de/en/article/news/kay-gottschalk-and-the-physics-of-cells
Press release - 08/01/2015 Biotech-Cluster Rhine-Neckar (BioRN) leads InnoLife consortium to success BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to 700 million euros and a total project volume of more than 2 billion euros, this is one of the largest publicly funded initiatives in the health sector worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biotech-cluster-rhine-neckar-biorn-leads-innolife-consortium-to-success
Article - 22/12/2014 The immune system – both weak and overreactive in the absence of CTLA4 The ability to recognise a pathogen and combat it effectively is certainly one of the most complex and sophisticated processes the human body has evolved. People with an immunodeficiency or autoimmune disease may have a genetic defect in one of the genes involved in the immune response. Working with immunologists from London scientists Desire Schubert and Prof. Dr. Bodo Grimbacher from the Centre for Chronic Immunodeficiency CCI at the Freiburg…https://www.gesundheitsindustrie-bw.de/en/article/news/the-immune-system-both-weak-and-overreactive-in-the-absence-of-ctla4
Article - 28/11/2014 Martin Plenio - turning Ulm’s quantum biology into a technology forge Quantum biology has the potential to become the next big research coup. Professor Martin Plenio, 46, director of the Institute of Theoretical Physics at Ulm University and one of the world’s leading quantum technologists, is right at the forefront. He has been Alexander von Humboldt Professor since 2009, and holds a part-time professorship at Imperial College London, where he was formerly chair of quantum physics.https://www.gesundheitsindustrie-bw.de/en/article/news/martin-plenio-turning-ulm-s-quantum-biology-into-a-technology-forge
Press release - 26/11/2014 Curetis Closes EUR 14.5 Million Extension of Series B Financing Curetis AG wins new investors QIAGEN and LSP-HEF, committing EUR 7 million. Hence Curetis is well financed into 2017. Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-closes-eur-14-5-million-extension-of-series-b-financing
Article - 20/10/2014 QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-pocket-sized-laboratories-for-the-efficient-identification-of-pathogens
Article - 13/10/2014 Personalised cancer therapy based on microRNA analysis microRNAs are not just required for the regulation of gene expression, their expression signatures also allow conclusions to be drawn on the type and progression of cancer. Sensovation AG is therefore working with partners from industry and clinical research to develop an automated microRNA analysis platform that can detect and evaluate microRNA signatures faster than has previously been possible. The system is designed to make it easier to…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-cancer-therapy-based-on-microrna-analysis
Part 2 - 06/10/2014 Expert interview: How are the prices of innovative diagnostic and medical devices determined? While there are specific regulations in Germany for the reimbursement of medicines, funding for molecular diagnostics products is complex and virtually non-existent. There is hardly any medical insurance cover for medical devices, which therefore tend to be sold on the open market. The question therefore arises as to how a reasonable price can be determined for innovative diagnostic methods and tools. In the second part of the interview conducted…https://www.gesundheitsindustrie-bw.de/en/article/news/expert-interview-how-are-the-prices-of-innovative-diagnostic-and-medical-devices-determined
Article - 29/09/2014 myPOLS Biotec UG - made-to-measure enzymes for diagnostics and research The company myPOLS Biotec UG, a spin-off from the University of Konstanz, specializes in services involving DNA and RNA polymerases and creates artificial enzymes by evolution in test tubes. These next-generation polymerases can be used for many research and diagnostics applications. myPOLS Biotec’s polymerases are promising enzymes for future applications with the potential to make the detection of pathogens and DNA analysis faster and easier. https://www.gesundheitsindustrie-bw.de/en/article/news/mypols-biotec-ug-made-to-measure-enzymes-for-diagnostics-and-research
Article - 08/09/2014 Molecular effects of traumatic stress After a traumatic experience, people often suffer not only mental, but also physical effects. Dr. María Moreno-Villanueva from the University of Konstanz has investigated the molecular effects of traumatic stress in people and has found a higher than normal number of DNA strand breaks. In the worst cases this can lead to diseases such as cancer. However, her study also shows that successful psychotherapy can reverse DNA damage. Her findings will…https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-effects-of-traumatic-stress
Article - 11/08/2014 dsl-Labor: developing PCR tests for medical diagnostics PCR has become a common application in medical diagnostics, in areas ranging from the detection of microbes to genetic testing. The demand for new tests is huge, given that there is a seemingly endless list of applications for which PCR can be used. dsl-Labor für Molekulargenetische Diagnostik specialises in the development of PCR tests and also gives advice and training to medical laboratory personnel. Veterinarians are among the company’s major…https://www.gesundheitsindustrie-bw.de/en/article/news/dsl-labor-developing-pcr-tests-for-medical-diagnostics
Article - 21/07/2014 Predicting the efficiency of cancer drugs using mathematical models A research consortium was established at the Stuttgart Research Center Systems Biology SRCSB at the University of Stuttgart in January 2013 with the goal of establishing models that help predict the action of targeted therapeutics. The scientists combine molecular biology experiments with complex mathematical models in order to achieve a holistic understanding of disease and therapy. https://www.gesundheitsindustrie-bw.de/en/article/news/predicting-the-efficiency-of-cancer-drugs-using-mathematical-models
Article - 14/07/2014 Andreas Marx – “Chemical Biology” of DNA polymerases Whether inside the cell or in molecular biology laboratories, the synthesis of DNA would not be possible without DNA polymerases. The regulation and application of this versatile enzyme family is the subject of research carried out by Prof. Dr. Andreas Marx at the University of Konstanz in Southern Germany. In addition to basic research into naturally occurring DNA polymerases, Marx deals with the development of novel polymerases that can be used…https://www.gesundheitsindustrie-bw.de/en/article/news/andreas-marx-chemical-biology-of-dna-polymerases
Article - 30/06/2014 Targeting epigenetic DNA modifications for the diagnosis of cancer Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer…https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-epigenetic-dna-modifications-for-the-diagnosis-of-cancer
Article - 28/04/2014 Sciomics: antibody microarrays and their broad range of applications Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of…https://www.gesundheitsindustrie-bw.de/en/article/news/sciomics-antibody-microarrays-and-their-broad-range-of-applications
Article - 07/04/2014 BIPSO GmbH – modern contrast agents for the entire world BIPSO GmbH, based in Singen, Germany, has been manufacturing contrast agents for applications in modern medical diagnostics since 2011. BIPSO is part of the Bracco Imaging Group, which is one of the world’s leading specialists in the diagnostic imaging business, and produces imaging agents mainly for Bracco’s sales organisations. The company has recently invested in the expansion of its manufacturing site in Singen with the goal of consolidating…https://www.gesundheitsindustrie-bw.de/en/article/news/bipso-gmbh-modern-contrast-agents-for-the-entire-world
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Article - 24/03/2014 Hain Lifescience GmbH: modern test systems help to heal Hain Lifescience GmbH is a biotechnology company that develops, manufactures and distributes molecular genetic test systems and instruments. The company was established by brothers David and Tobias Hain in 1988 and employs over 100 people at its headquarters in the city of Nehren in the district of Tübingen. Hain Lifescience also has four subsidiaries abroad. The company focusses on the development of test systems for the early and rapid…https://www.gesundheitsindustrie-bw.de/en/article/news/hain-lifescience-gmbh-modern-test-systems-help-to-heal
Article - 24/03/2014 DNA – from Watson and Crick to modern molecular biology Watson and Crick deciphered the structure of DNA around 60 years ago and thus provided the key to understanding how genetic information is passed on. Since this discovery, which laid the foundation for molecular biology, new insights and developments have significantly changed many research areas and have also found their way into our everyday lives. DNA sequencing, genetic fingerprinting or personalised medicine – Watson and Crick’s heritage is…https://www.gesundheitsindustrie-bw.de/en/article/news/dna-from-watson-and-crick-to-modern-molecular-biology
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Article - 17/02/2014 Personalised tumour diagnostics with high-throughput sequencing CeGaT GmbH Center for Genomics and Transcriptomics in Tübingen is one of the first organisations that have managed to combine human genetic diagnostics with high-throughput sequencing for the diagnosis of specific tumour variants. CeGat researchers have developed diagnostic panels that they use to study more than 550 tumour-relevant genes simultaneously. The identification of genetic changes provides a more detailed diagnosis of tumours and helps…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-tumour-diagnostics-with-high-throughput-sequencing
Article - 20/01/2014 Curetis AG: Miniaturised laboratory for the simple, rapid and reliable diagnosis of serious infections Acute pneumonia usually leaves doctors with no choice the situation can quickly become life threatening requiring doctors to act quickly. Instead of waiting for laboratory results they often prescribe an antibiotic that is effective against numerous bacterial species in the hope that it will also work against the bacterium that has caused the inflammation in the lung tissue. Curetis AG from Holzgerlingen close to Stuttgart has developed a…https://www.gesundheitsindustrie-bw.de/en/article/news/curetis-ag-miniaturised-laboratory-for-the-simple-rapid-and-reliable-diagnosis-of-serious-infections
Article - 13/01/2014 DIARECT AG – development and production of immunodiagnostics components Founded by Dr. Heinz Haubruck and Prof. Dr. Bodo Liedvogel in 1998, the biotechnology company DIARECT AG (DIAgnostic by RECombinant Technology) from Freiburg sells tried and tested and new products. The company produces proteins, nucleoproteins and assay components for the diagnostics sector. These products enable the reliable identification of autoimmune disorders and infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/diarect-ag-development-and-production-of-immunodiagnostics-components
Article - 29/11/2013 QIAGEN Lake Constance: a “disk player” for rapid diagnoses The diagnosis of infectious diseases frequently not only depends on the reliable identification of the pathogenic species that has caused them, but also on obtaining rapid results in order to immediately initiate appropriate therapy or further diagnostic measures. Tests are normally carried out in central laboratories, samples need to be sent to the laboratories and the results are rarely immediate. As part of the BMBF-funded project “ResCheck”,…https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-a-disk-player-for-rapid-diagnoses
Article - 11/11/2013 Vitaphone GmbH - innovative telemedicine Vitaphone GmbH from Mannheim is a leading international telemedical service provider. Its services range from telecardiological functional diagnostics, 24/7 telemonitoring of risk patients to integrative care management of chronically ill patients. Vitaphone is particularly involved in the application of structured telemonitoring-based therapy programmes for patients with heart failure. https://www.gesundheitsindustrie-bw.de/en/article/news/vitaphone-gmbh-innovative-telemedicine
Dossier - 04/11/2013 Biotechnology – driver of innovation in the pharmaceutical industry The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-driver-of-innovation-in-the-pharmaceutical-industry
Article - 19/08/2013 The Heidelberg practice of whole-genome sequencing After two years’ work, scientists from Heidelberg have now presented their opinion on the ethical and legal consequences of the total sequencing of the human genome. The paper presents principles and practical recommendations aimed at maintaining the balance between the wellbeing and interests of patients on the one hand and the freedom of research and clinical progress on the other.https://www.gesundheitsindustrie-bw.de/en/article/news/the-heidelberg-practice-of-whole-genome-sequencing
Article - 19/08/2013 Brain mapping – ‘eavesdropping’ on the brain Although numerous scientists have spent decades exploring the brain and many things are already known the brain is still considered one of the greatest mysteries of science. While structural elements such as cell and axon distribution can only be mapped post mortem motor and sensory functions can only be studied in vivo i.e. using living organisms. Dr. Tonio Ball and his colleagues at the BrainLinks-BrainTools cluster of excellence at the…https://www.gesundheitsindustrie-bw.de/en/article/news/brain-mapping-eavesdropping-on-the-brain
Article - 12/08/2013 A complete exome sequence in one week The exome is the part of the genome that is formed by exons i.e. the DNA regions that code for proteins and other functional products. Though comprising only about 1 of the total genome the majority of disease-causing mutations occur in the exome. Selectively sequencing the coding regions of the genome is quicker than whole-genome sequencing. Therefore exome sequencing plays an important role in the diagnosis of genetic diseases and cancer.…https://www.gesundheitsindustrie-bw.de/en/article/news/a-complete-exome-sequence-in-one-week
Article - 12/08/2013 Sensovation AG: a special camera for rapid allergy diagnosis Between 20 and 30 million Germans suffer from allergies to house dust mites, pollen and many other allergens¹. The diagnosis of allergies is usually a rather time-consuming process as more than 20,000 potential allergens need to be tested in order to identify the allergen that causes a patient’s particular symptoms². Sensovation AG has developed a technology that allows the parallel analysis of 20 allergens and which has the potential to simplify…https://www.gesundheitsindustrie-bw.de/en/article/news/sensovation-ag-a-special-camera-for-rapid-allergy-diagnosis
Dossier - 05/08/2013 Progress expands bioethical boundaries Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. However, rapid progress in genetic engineering and cell biology means that it is now necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be…https://www.gesundheitsindustrie-bw.de/en/article/dossier/progress-expands-bioethical-boundaries
Press release - 22/07/2013 BIOPRO Baden-Württemberg's international relations bring Heidelberg-based Medicyte GmbH in contact with new distribution partner BIOPRO Baden-Württembergs business development activities have led to the establishment of a new distribution partnership between Heidelberg-based Medicyte GmbH and Dutch Westburg BV. When BIOPRO searches for international partners for Baden-Württemberg companies the state agency often makes use of its international network partners and in this case BIOPROs contact with the Netherlands Business Support Office Stuttgart NBSO brought the desired…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biopro-baden-wuerttemberg-s-international-relations-bring-heidelberg-based-medicyte-gmbh-in-contact
Dossier - 01/07/2013 Electrophysiology – from cardiac pacemakers to drug discovery Electrochemical reactions are involved in many processes in the human organism. Electrophysiology is the study of the central processes of electrical and chemical interaction and communication between neurons and muscle cells, including the transmission and processing of signals in the nerves and the subsequent contraction of the muscles. For example, electrophysiology studies examine the rhythm which which our heart pumps blood through the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/electrophysiology-from-cardiac-pacemakers-to-drug-discovery
Article - 03/06/2013 With metabolomics food analytics goes all the way In the not-too-distant future, food analysts hope they will be able do more than just detect mycotoxin traces and determine the concentration of individual nutrients such as vitamin C. Their ambition is in fact much broader: “We would like to understand the nutritional and physiological effect of food,” said Prof. Sabine Kulling from the Max Rubner Institute in Karlsruhe. As with other life sciences areas, metabolomics is seen as a key technology…https://www.gesundheitsindustrie-bw.de/en/article/news/with-metabolomics-food-analytics-goes-all-the-way
Article - 13/05/2013 Cardiomyopathies and epigenetic inheritance Epigenetic mechanisms, along with gene mutations, have been shown to play important roles in the development of heart diseases. Researchers from Heidelberg have discovered that the methylation of two specific genes has an impact on the development of dilated cardiomyopathy. These epigenetic modifications have the potential to be used as molecular markers and improve the diagnosis and therapy of these particular heart diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/cardiomyopathies-and-epigenetic-inheritance
Dossier - 13/05/2013 The human proteome – the next major goal The “Human Proteome Project”, a ten-year global initiative that is making a systematic effort to map all human proteins, has moved from the planning to the experimental stage. How significant and how effective the project will be depends on how much the resources offered are used by proteome researchers and on the data that the researchers bring into the project. https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-human-proteome-the-next-major-goal
Press release - 30/04/2013 Impressions from the 2013 BIO International Convention in Chicago A trade fair turns 20 and an industrial sector is coming of age. Where does BIO stand today? The number of exhibitors has slightly decreased the conference is characterised by general themes and trends and partnering has become the most important and indispensable part of the global event for biotechnology. What was once a gold rush atmosphere has given way to an experienced self-confidence about the economic importance of biotechnology. https://www.gesundheitsindustrie-bw.de/en/article/press-release/impressions-from-the-2013-bio-international-convention-in-chicago
Article - 29/04/2013 ‘Autotech meets Biotech’ – current status and outlook Intensive cooperation between the engineering-driven sectors and the biotechnology sector is a prerequisite for driving forward automation in the field of biotechnology. The Engineering – Life Sciences – Automation (ELSA) cluster initiative of BioRegio STERN Management GmbH aims to promote cross-industry cooperation. A study entitled ‘Biotech meets Autotech’, which was carried out as part of the ELSA project, provides insights into the current…https://www.gesundheitsindustrie-bw.de/en/article/news/autotech-meets-biotech-current-status-and-outlook
Article - 15/04/2013 Molecule-specific diagnosis of metabolic diseases In cooperation with the company Centogene AG Prof. Dr. Michael Przybylski from the Steinbeis Transfer Center for Biopolymer Analysis and Biomolecular Mass Spectrometry at the University of Konstanz has developed a method that involves a novel substance class and enables the parallel measurement of enzyme activity based on fluorometry and mass spectroscopy. The method for which the inventors have recently filed a patent application forms the basis…https://www.gesundheitsindustrie-bw.de/en/article/news/molecule-specific-diagnosis-of-metabolic-diseases
Article - 08/04/2013 Integrated infrastructures for medical science The annual TMF conference in Heidelberg dealt with the need for integrated science infrastructures for the advancement of medical research. The major focus was on quality criteria for medical biomaterial banks and the establishment of the German Biobank Registry as the core of a central IT infrastructure, with the overall aim of creating the right conditions for resource-saving medical research excellence in Germany. https://www.gesundheitsindustrie-bw.de/en/article/news/integrated-infrastructures-for-medical-science
Article - 25/03/2013 Epigenetics for personalised cancer care for women Every year in the EU, 45,300 women are diagnosed with ovarian cancer and 330,000 with breast cancer. Ovarian cancer has a mortality rate of around 64% and breast cancer around 27%*. The EU-funded research project EpiFemCare aims at improving cancer detection and subsequent patient care. The research project aims to develop blood tests based on epigenetic DNA modifications, i.e. the methylation of the base cytosine, for the identification of…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetics-for-personalised-cancer-care-for-women
Dossier - 25/03/2013 Biotechnology goes automated Processes that previously required pipetting analysis and production to be carried out manually are increasingly now controlled by automated systems. However this has not necessarily involved a complete reinvention of the wheel instead automation systems used in the plant construction and mechanical engineering sectors are being adapted and optimised for application in the life sciences. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-goes-automated
Article - 25/02/2013 Molecular monitoring of premature infants Premature births are not uncommon in Germany where around seven percent of newborns are born before week 37 of pregnancy. The WHO estimates that the numbers of preterm births are growing due to the increasing age of mothers. Doctors caring for the tiny patients are faced with a dilemma because regular blood samples required for the clinical monitoring of important blood parameters cannot be taken due to the infants low body volume.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-monitoring-of-premature-infants
Article - 04/02/2013 Combining bio- and medtech for the diagnosis of cardiac diseases The Department of Cardiology at Heidelberg University Hospital and Siemens Corporate Technology have been working together since 2011 to develop new software that improves the diagnosis of heart diseases. The new software analyses and manages data related to the genetic causes of cardiomyopathy and presents the data to physicians in a clear manner. Specific microRNAs in the blood of patients have the potential of being used as new biomarkers,…https://www.gesundheitsindustrie-bw.de/en/article/news/combining-bio-and-medtech-for-the-diagnosis-of-cardiac-diseases
Article - 04/02/2013 SYGNIS Pharma - the "new" one: development and commercialisation of molecular diagnostics products Heidelberg-based SYGNIS Pharma AG is to discontinue its therapeutic R&D projects targeting human nervous system diseases and will in future focus on the research and development of novel molecular biology technologies, including DNA amplification and sequencing as well as drug screening.https://www.gesundheitsindustrie-bw.de/en/article/news/sygnis-pharma-the-new-one-development-and-commercialisation-of-molecular-diagnostics-products
Article - 28/01/2013 Epigenetics and childhood blood cancer Juvenile myelomonocytic leukaemia JMML is the most common chronic cancer of the blood in children and tends to have a poor response to chemotherapy. Prof. Dr. Christian Flotho and his team from the Centre of Paediatric and Adolescent Medicine in Freiburg have shown that epigenetic mechanisms play a key role in the pathogenesis of JMML. As part of a German Research Foundation priority programme the researchers from Freiburg are working on…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetics-and-childhood-blood-cancer
Article - 31/12/2012 Diagnosis of myocardial infarction: a drop of blood is all that is required Can myocardial infarction be diagnosed with a single drop of blood? The answer is yes: a new application of the ESEQuant Lateral Flow System developed by QIAGEN now makes this possible. The system, which is able to identify a broad range of bacterial and viral pathogens, including HIV, influenza virus and Chlamydia, was originally developed at the company’s site in Stockach. It has recently been adapted for use in the diagnosis of myocardial…https://www.gesundheitsindustrie-bw.de/en/article/news/diagnosis-of-myocardial-infarction-a-drop-of-blood-is-all-that-is-required
Article - 28/12/2012 When cells go out of control – researchers to unveil the secret of cell ageing The process of ageing appears, at least at first sight, to be fairly tangible and is visible both at individual and societal level. Nevertheless, science has not yet come up with detailed insights into the physiology of ageing. Jörg Bergemann, Professor of Biomedical Engineering at the Albstadt-Sigmaringen University of Applied Sciences, is studying the processes of ageing in skin cells in a project that has recently been granted funding by the…https://www.gesundheitsindustrie-bw.de/en/article/news/when-cells-go-out-of-control-researchers-to-unveil-the-secret-of-cell-ageing
Dossier - 20/12/2012 Medical technology – serving healthcare Modern healthcare would be impossible without medical technology. The achievements in medical technology are indispensable for our health and quality of life. The range of medical technology available covers surgical instruments and implants to diagnostic methods and medical devices.https://www.gesundheitsindustrie-bw.de/en/article/dossier/medical-technology-serving-healthcare
Article - 17/12/2012 Rare diseases – the long road to correct diagnosis and treatment Rare diseases are conditions that are too often neglected by research, industry and medicine. Here we use Wilson’s disease as an example to illustrate the particular problems associated with research into and treatment of rare diseases and to provide information on measures that can be taken to improve the situation of people with rare diseases. These measures include central treatment and care institutions and programmes like the Wilson’s…https://www.gesundheitsindustrie-bw.de/en/article/news/rare-diseases-the-long-road-to-correct-diagnosis-and-treatment
Press release - 17/12/2012 Curetis AG initiates clinical trial in the U.S. towards FDA clearance Curetis AG announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more than 2,000 hospitalized patients suspected to have a lower respiratory tract infection and several…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-initiates-clinical-trial-in-the-u-s-towards-fda-clearance
Press release - 05/12/2012 Next Generation Sequencing of GATC Biotech AG accredited by German DAkkS Being the first in Europe, the Next Generation Sequencing Laboratories of the Constance Genome and Diagnostics Centre has been accredited according to ISO 17025 from the national accreditation body for the Federal Republic of Germany (DAkks). The independent governmental institution has acknowledged the high quality standard of the sequencing service on technology platforms Illumina HiSeq and Roche GSFLX sequencing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-generation-sequencing-of-gatc-biotech-ag-accredited-by-german-dakks
Dossier - 26/11/2012 Genetic diagnostics: technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable
Press release - 26/11/2012 Project "DiscoGnosis" aims to develop a rapid malaria test An estimated 220 million people become infected with malaria each year the disease is often lethal. The infected suffer from a high fever. As this is also the case with other germs however it is important to conduct a rapid and precise analysis to determine the cause of the disease for a successful therapy. A team of researchers aims to develop a rapid test of this kind within the context of the project DiscoGnosis. The project is being…https://www.gesundheitsindustrie-bw.de/en/article/press-release/project-discognosis-aims-to-develop-a-rapid-malaria-test
Press release - 22/11/2012 CeGaT and Genomatix are finalists of Boston Children’s Hospital’s CLARITY challenge CeGaT (Center for Genomics and Transcriptomics) GmbH, the Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bonn and Genomatix Software GmbH were announced as finalist (Top 3) of the CLARITY challenge, organized by Boston Children’s Hospital.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-and-genomatix-are-finalists-of-boston-children-s-hospital-s-clarity-challenge
Article - 19/11/2012 Uncovering the genetics of prostate cancer The prostate genome project, which is part of the International Cancer Genome Consortium, is focused on the genetic and epigenetic causes of the development and progression of this highly variable cancer and finding markers that enable the reliable diagnosis of the disease. The German research groups involved in the project are coordinated by the German Cancer Research Center and concentrate on prostate cancer patients under 50 years of age, as…https://www.gesundheitsindustrie-bw.de/en/article/news/uncovering-the-genetics-of-prostate-cancer
Press release - 12/11/2012 Searching for new strategies against prostate cancer The European Research Council (ERC) has announced that Roland Schüle, Scientific Director at the Department of Urology, University of Freiburg Medical Centre has been awarded an ERC Advanced Grant. Professor Schüle will receive €2.5 million for a period of 5 years for his research proposal to identify and characterize the molecular and physiological functions of the epigenetic enzyme LSD1 and to explore its role in prostate cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/searching-for-new-strategies-against-prostate-cancer